Background: Prenatal folic acid supplementation is recommended to prevent birth de-
| INTRODUCTION
Wheezing and atopic dermatitis are common and associated with substantial morbidity in early childhood and often precede the onset of asthma later in childhood. 1, 2 Genetics and host factors have been indicated in the complex etiology of atopic diseases, as have environmental and nutritional exposures. 3 High prenatal folic acid exposure has been studied as a risk factor for childhood atopic diseases, due in part to its recognized capacity to epigenetically modify DNA. 4 Some observational studies have suggested that higher folic acid during pregnancy may be associated with increased risk of allergic and respiratory phenotypes in offspring, [5] [6] [7] [8] [9] [10] while other studies found null [11] [12] [13] [14] or inverse associations. 13, 15 Women of childbearing age are advised to consume a daily supplement of 400-800 μg/d of folic acid to reduce the risk of infants born with neural tube defects. 16 In the USA, mandatory folic acid fortification of many enriched cereal and grain products has been implemented since 1998 to achieve sufficient intake, particularly among women who may have unplanned pregnancies. 17 To date, most studies of prenatal folate exposure and childhood atopic diseases have been conducted in countries without mandatory fortification, and many studies did not capture blood folate levels. 6, 11, 12, 14 Relative to non-fortified populations, women in the US may experience high levels of folate due to combined exposure to food fortification and prenatal supplementation. However, the relationship between prenatal folate exposure using biomarkers and childhood atopic disease has not been well characterized among US women and children. Thus, we sought to examine the relationship of maternal prenatal folate status with child wheeze in the 3rd year of life and atopic dermatitis at age 3 years in a prenatal US cohort of mother-child dyads.
| METHODS

| Study population
Participants were enrolled in the Conditions Affecting Neurocognitive Development in Early Childhood (CANDLE) study, a prospective prenatal cohort in Memphis, Tennessee. Briefly, 1503 healthy women, 16-40 years of age, with a singleton pregnancy, and intent to deliver at a study hospital were enrolled during 16-28 weeks estimated gestational age (EGA) from community-based obstetric practices between 2006 and 2011. 18, 19 The CANDLE study included 2nd and 3rd trimester and delivery visits during which we obtained demographics, psychosocial and medical histories, and biospecimens. Mother-child dyads were followed with in-person study visits annually. In total, there were 1457 live-births. Of these, 1049 dyads had a visit at age 3 years and 985 had a visit that included assessment of child respiratory and atopic disease ( Figure 1 ). Low birthweight (LBW < 2500 g) and/or preterm (EGA < 37 weeks) (n = 110) infants were excluded to study the relationship between prenatal folate levels and atopic diseases in children without potential preexisting lung disease. We restricted analyses to African
American and White women because women of other races were too few to study (n = 17). The analytical sample included 858 dyads. The study was approved by the Institutional Review Boards of University of Tennessee Health Sciences Center (UTHSC) and Vanderbilt University.
| Maternal blood collection and laboratory measurements
Whole blood was collected at 2nd and 3rd trimester visits. Plasma was separated by centrifuging at 1278 g for 10 minutes and stored at −70°C at UTHSC until analysis. Folate levels were assessed by a Lactobacillus casei microbiological assay at the University of Alabama at Birmingham. 20 The minimum detection limit of the assay was 3 ng/ mL, with 4.8%-5.9% intra-assay and 5.5%-6.5% inter-assay variability for the laboratory assay controls.
| Assessment of current wheeze and atopic dermatitis at age 3 years
We defined current wheeze as parental report of "wheezing or whistling in the chest at any time in the past" 21 and one or more episodes of wheezing within the past 12 months, which captured current wheeze in the 3rd year of life. Atopic dermatitis was based on affirmative response to the question, "has a doctor or a healthcare provider ever diagnosed your child with eczema or atopic dermatitis" administered during the 3rd year of life.
| Statistical analysis
We report median and interquartile ranges (IQR) for continuous and frequencies and proportions for categorical measures. Maternal and child characteristics were compared by current wheeze and atopic dermatitis status using Kruskal-Wallis and chi-square tests for continuous and categorical variables.
Current wheeze and atopic dermatitis were modeled as binary outcomes. Folate concentration was included as continuous predictor (10 ng/mL change) in unadjusted and adjusted logistic regression analyses. A restricted cubic spline model with 3 knots was used to test the nonlinear relationships between prenatal folate levels and the log-odds of current wheeze and atopic dermatitis. Folate was also analyzed as a dichotomous exposure: < or ≥20 ng/mL. Plasma folate levels >20 ng/mL (~45 nmol/L) have been considered supraphysiologic, with some concern for harmful effects at this level in certain clinical populations. 22, 23 Folate was also characterized by quartiles.
We modeled 2nd and 3rd trimester folate levels separately for each approach.
Covariates were selected a priori based on the literature and plausible associations with primary exposure and outcome. [6] [7] [8] Multivariable analyses were adjusted for maternal age at enrollment, self-reported race (African American/White), education (less than high-school/ high-school or beyond), prenatal smoking (yes/no), asthma (yes/no), pre-pregnancy body mass index (BMI, Kg/m 2 ), 2nd trimester vitamin D levels, parity (none/≥1), delivery route (vaginal/cesarean), and child sex and birthweight. Because there was 12% missing data on maternal report of breastfeeding, we conducted sensitivity analysis on the subset that included breastfeeding (yes/no) as a potential covariate. For the subset that completed a 2nd trimester food-frequency questionnaire (FFQ), intake of other nutrients important for DNA methylation (vitamin B 6 , B 12 , choline, methionine, and betaine) was estimated 18 and was tested as potential confounders in multivariable models using a 10% change in estimate criteria.
We conducted sensitivity analyses including dyads with infants born preterm and/or LBW in the models of continuous and dichotomized folate measures with child current wheeze and adjusted for birthweight and EGA along with other covariates. 
| RESULTS
Of the 858 dyads, 63.4% of mothers were African American, and more than half had less than high-school education (53.9%) and on (Table S1 ).
Approximately 20% of children (174/849) had current wheeze in the 3rd year of life and 27% (231/857) had atopic dermatitis. Children with current wheeze were more likely to be males (57%, P < .01); for atopic dermatitis, there were no differences by sex. Children with atopic dermatitis were more likely to have mothers who were African American or on Medicaid than those without (Table 1) .
Median (IQR) 2nd and 3rd trimester folate levels were 22.6 (15.9-30.0) ng/mL (n = 852) and 23.1 (16.1-30.0) ng/mL (n = 818), respectively ( Table 1 ). There was a modest correlation (spearman rho = 0.5; P < .001) between 2nd and 3rd trimester folate levels.
Among women for whom FFQs were available (n = 758), 95% reported consuming folic acid supplements during 2nd trimester (Table 1) . Women with higher folate (≥20 ng/mL) were more likely to be older, White, more educated, have higher vitamin D levels, and were more likely to breastfeed than those with lower levels (<20 ng/ mL) ( Table S2 ).
The relative odds of current wheeze in the 3rd year of life were approximately one-third lower in children born to mothers with 2nd trimester folate levels ≥20 ng/mL vs <20 ng/mL (adjusted OR
[aOR] = 0.67, 95% CI = 0.46, 0.97). We did not detect a statistically significant association with current wheeze when 2nd trimester levels were modeled continuously in unadjusted (OR: 0.91, 95% CI = 0.80, 1.05) or adjusted logistic regression models (adjusted OR
[aOR] = 0.97, 95% CI = 0.84, 1.12) ( Table 2) . We did not observe significant associations or a dose-response relationship when prenatal folate was tested as quartiles (Table S3) .
T The tests for nonlinear relationships between prenatal folate levels and child outcomes were also non-significant. We did not detect a statistically significant relationship between 3rd trimester folate and current wheeze in dichotomous (aOR = 0.91, 95% CI = 0.62, 1.34) or continuous models (aOR = 1.01, 95% CI = 0.86, 1.18) ( Table 2) Maternal 2nd trimester folate levels were not associated with child atopic dermatitis (Table 3) . In unadjusted analyses, we observed decreased relative odds of atopic dermatitis with a 10 ng/mL increase in maternal 3rd trimester folate levels and with 3rd
trimester folate levels ≥20 ng/mL. However, these differences did not reach statistical significance in multivariable models (aOR = 0.87
[95% CI = 0.75, 1.01] for continuous; aOR = 0.84 [95% CI = 0.59,
1.18] for dichotomous folate).
Results were not significantly different when dyads with infants born preterm and/or LBW were included in models (Table S4) .
Additionally, sensitivity analyses that included insurance status or intakes of methyl donors (vitamin B6, B12, choline, methionine and betaine) did not appreciably change the results (data not shown).
| DISCUSSION
We investigated the association between prenatal plasma folate and early childhood wheeze and atopic dermatitis, two childhood conditions that commonly precede asthma. In our cohort, over half of the women had high prenatal folate levels (above 20 ng/mL). This is in contrast with other studies with much lower prenatal folate levels. 5, 7, 8, 13 Despite concerns that high folate exposure may be associated with adverse health effects, we observed that these higher 2nd trimester folate levels were associated with a modest decrease in relative odds of child wheeze in the 3rd year of life. While we cannot rule out unmeasured confounding, this association was robust to adjustment from multiple potential confounders, suggesting the protective association with folate is not driven by factors such as higher socioeconomic status among the highly exposed. Notably, we did not observe a similar association using 3rd trimester measurements.
Our finding of a decreased risk of current wheeze in the third year of life among children with higher maternal plasma folate (≥20 ng/mL) is in line with findings from a nested case-control study using the KOALA cohort in the Netherlands. 13 A dose-related decreased odds of asthma at 6-7 years were found with higher maternal 3rd trimester erythrocyte folate levels. 13 In contrast, the Norwegian Mother at 3 years in children born to mothers in the highest plasma folate levels (>17.8 nmol/L or ~8 ng/mL) relative to children with mothers in the lowest levels (folate <5.5 nmol/L or ~2.5 ng/mL). 8 A recent MoBa study reported a modest but increased risk of asthma at age 7 years with higher maternal total folate intake. 5 However, 2nd trimester maternal plasma folate levels (median 8.7 nmol/L or ~3.8 ng/mL) were not associated with asthma in a subset of 2681 children. 5 Folic acid supplement use or prescription fills have been associated with increased risk of child wheeze or asthma in populations with 6 and without mandatory folic acid fortification. [9] [10] [11] [12] The contrasting results between studies of self-reported prenatal folate intake or supplement use and those measuring circulating folate levels could be due to potential challenges in accurately capturing usual intake or differences in timing of the exposure. Furthermore, other lifestyle factors, genetic polymorphisms, gut microbiome, or other nutrients could affect folate absorption, metabolism, blood folate status, and subsequent associations with child outcomes. 24 We did not find statistically significant associations between 2nd
or 3rd trimester folate and child atopic dermatitis. Our results are consistent with those of an Australian Birth Cohort Study which reported that 3rd trimester serum folate levels were not associated with infant atopic dermatitis. 25 In contrast, the Generation R study found slightly increased atopic dermatitis at age 4 in Dutch children born to mothers with 1st trimester plasma folate >16.2 nmol/L (~7 ng/mL), 7 and higher mid-pregnancy serum folate (>9.5 ng/mL) was associated with decreased atopic dermatitis at 2 years in a South Korean cohort. 15 The mechanisms behind potential effects of folate on child wheeze are not clear. Potentially, folate may act as an antioxidant 26 or may reduce inflammation via altering the immune system through epigenetic changes. 27 Wheezing is not always related to atopy, and different immune mechanisms may be involved in atopic and non-atopic wheezing, 28 which may explain somewhat differential associations observed. 7, 13, 28 There are limitations to consider. We measured plasma folate, which reflects short-term folate status (~3 weeks). However, levels
were assessed at defined time points and the 2nd and 3rd trimester folate levels were significantly correlated, indicating relatively stable folate status across pregnancy. Although we used parental report to characterize outcomes, 29 previous studies have found good agreement between the parent report and physician diagnosis of atopic diseases. 7 Moreover, we captured wheeze in the 3rd year of life as opposed to wheezing that occurred in the first 2 years; it is therefore less likely to be attributed to viral bronchiolitis. While we adjusted for maternal asthma, this did not include other atopic diseases, however maternal asthma history is one of the strongest predictors of childhood asthma. 30 Lost to follow-up is another limitation; however, included participants were similar to original cohort in that they were predominantly African American, low-income dyads with high maternal prenatal folate levels. Our study sample remains an understudied population with wide generalizability In summary, in this prospective US cohort of dyads, more than half were exposed to 20 ng/mL or greater folate during pregnancy.
High plasma folate levels in the 2nd trimester were associated with decreased relative odds of child wheeze in the 3rd year of life.
Concerns of potential harmful effects of high maternal gestational folate levels on early childhood wheeze were not supported in this setting.
